Restricted accessEditorialFirst published online 2020-07
Editorial Comment on: “Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Centre Prospective Non-Randomized Trial” by Gallioli et al.
VergesDP, LallasCD, HuboskySG, et al.Endoscopic treatment of upper tract urothelial carcinoma. Curr Urol Rep, 2017; 18:31.
2.
GallioliA, BoissierR, TerritoA, et al.Adjuvant single-dose upper urinary tract instillation of Mitomycin C after therapeutic ureteroscopy for upper tract urothelial carcinoma: A single-centre prospective non-randomized trial. J Endourol, 2020; 34:573–580.
3.
KeeleyFX, BagleyDH. Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. J Urol, 1997; 158:2074–2077.
4.
CutressML, StewartGD, Wells-ColeS, et al.Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int, 2012, 110:1608–1617.
5.
CornuJ, RouprêtM, CarpentierX, et al.Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol, 2010; 28:151–156.
6.
AboumarzoukOM, SomaniB, AhmadS, et al.Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma. Urol Ann, 2013; 5:184–189.
7.
Martínez-PiñeiroJA, García MatresMJ, Martínez-PiñeiroL. Endourological treatment of upper tract urothelial carcinomas: Analysis of a series of 59 tumors. J Urol, 1996; 156:377–385.
8.
MetcalfeM, WagenheimG, XiaoL, et al.Induction and maintenance adjuvant mitomycin C topical therapy for upper tract urothelial carcinoma: Tolerability and intermediate term outcomes. J Endourol, 2017; 31:946–953.
9.
RastinehadAR, OstMC, VanderbrinkBA, et al.A 20-year experience with percutaneous resection of upper tract transitional carcinoma: Is there an oncologic benefit with adjuvant Bacillus Calmette Guérin therapy?. Urology, 2009; 73:27–31.
10.
OrihuelaE, SmithAD. Percutaneous treatment of transitional cell carcinoma of the upper urinary tract. Urol Clin North Am, 1988; 15:425–431.
11.
ThalmannGN, MarkwalderR, WalterB, et al.Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol, 2002; 168:1381–1385.
12.
GallioliA, BoissierR, TerritoA, et al.Adjuvant single-dose upper urinary tract instillation of mitomycin C after therapeutic ureteroscopy for upper tract urothelial carcinoma: a single-centre prospective non-randomized trial. J Endourol, 2020; 34:573–580.
13.
PollardME, LevinsonAW, ShapiroEY, et al.Comparison of 3 upper tract anticarcinogenic agent delivery techniques in an ex vivo porcine model. Urology, 2013; 82:1451.
14.
LiuZ, NgJ, YuwonoA, LuY, TanYK. Which is best method for instillation of topical therapy to the upper urinary tract? An in vivo porcine study to evaluate three delivery methods. Int Braz J Urol, 2017; 43:1084–1091.
15.
KleinmannN, MatinSF, PierorazioPM, et al.Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): An open-label, single-arm, phase 3 trial. Lancet Oncol, 2020; 21:776–785.
16.
DoninNM, DuarteS, LenisAT, et al.Sustained-release formulation of mitomycin C to the upper urinary tract using a thermosensitive polymer: A preclinical study. Urology, 2017; 99:270–277.
17.
LiourdiD, KallidonisP, KyriazisI, et al.Evaluation of the distribution of Paclitaxel by immunohistochemistry and nuclear magnetic resonance spectroscopy after the application of a drug-eluting balloon in the porcine ureter. J Endourol, 2015; 29:580–589.
18.
BarrosAA, BrowneS, OliveiraC, et al.Drug-eluting biodegradable ureteral stent: New approach for urothelial tumors of upper urinary tract cancer. Int J Pharm, 2016; 513:227–237.
